Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ELMD NYSE:INFU NASDAQ:NEPH NASDAQ:PROF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELMDElectromed$19.02-3.0%$19.65$13.74▼$35.56$159.50M0.3882,225 shs52,034 shsINFUInfuSystem$9.61+0.1%$6.65$4.61▼$9.97$196.29M1.81168,401 shs274,134 shsNEPHNephros$4.02-1.5%$3.80$1.36▼$5.00$42.61M1.1127,315 shs6,144 shsPROFProfound Medical$4.60-0.9%$5.80$3.89▼$9.71$138.23M0.5279,776 shs86,100 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELMDElectromed+2.35%-0.61%+8.16%-3.64%+33.22%INFUInfuSystem-0.21%+3.00%+74.23%+65.52%+39.13%NEPHNephros-1.21%-0.97%+14.29%+55.13%+120.54%PROFProfound Medical+1.31%-14.86%-16.40%-9.55%-51.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELMDElectromed1.7504 of 5 stars2.03.00.00.02.01.71.3INFUInfuSystem3.4056 of 5 stars2.05.00.00.02.44.21.9NEPHNephros1.6596 of 5 stars3.53.00.00.00.60.80.0PROFProfound Medical1.7719 of 5 stars3.51.00.00.01.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELMDElectromed 4.00Strong Buy$33.5076.13% UpsideINFUInfuSystem 4.00Strong Buy$12.5030.07% UpsideNEPHNephros 3.00Buy$5.5036.82% UpsidePROFProfound Medical 3.00Buy$11.00139.13% UpsideCurrent Analyst Ratings BreakdownLatest NEPH, INFU, PROF, and ELMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025NEPHNephrosMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.50 ➝ $6.007/22/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$29.007/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELMDElectromed$61.44M2.60$0.46 per share41.36$5.10 per share3.73INFUInfuSystem$139.89M1.40$0.75 per share12.79$2.47 per share3.89NEPHNephros$14.16M3.01$0.02 per share206.39$0.91 per share4.42PROFProfound Medical$10.68M12.94N/AN/A$1.31 per share3.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELMDElectromed$5.15M$0.7925.36∞N/A11.34%15.71%13.37%N/AINFUInfuSystem$870K$0.23160.1931.00N/A1.12%2.78%1.41%N/ANEPHNephros$70K$0.1233.50∞N/A7.95%14.89%11.64%11/6/2025 (Estimated)PROFProfound Medical-$27.82M-$1.46N/AN/AN/A-343.97%-89.74%-73.06%11/6/2025 (Estimated)Latest NEPH, INFU, PROF, and ELMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PROFProfound Medical-$0.43-$0.52-$0.09-$0.52$4.75 million$2.21 million8/7/2025Q2 2025NEPHNephros-$0.0250$0.02+$0.0450$0.02$3.60 million$4.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELMDElectromedN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELMDElectromedN/A5.104.74INFUInfuSystem0.501.981.59NEPHNephrosN/A5.414.14PROFProfound Medical0.118.5310.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELMDElectromed40.82%INFUInfuSystem71.13%NEPHNephros41.10%PROFProfound Medical47.86%Insider OwnershipCompanyInsider OwnershipELMDElectromed14.00%INFUInfuSystem10.20%NEPHNephros6.70%PROFProfound Medical1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELMDElectromed1608.39 million7.36 millionOptionableINFUInfuSystem41020.43 million19.10 millionOptionableNEPHNephros3010.60 million9.89 millionNot OptionablePROFProfound Medical15030.05 million29.60 millionOptionableNEPH, INFU, PROF, and ELMD HeadlinesRecent News About These CompaniesProfound Medical is a buy, Leede saysAugust 20 at 2:38 AM | cantechletter.comCProfound Medical (NASDAQ:PROF) Issues Quarterly Earnings Results, Misses Expectations By $0.09 EPSAugust 18 at 9:35 PM | marketbeat.comProfound Medical: Smokes Is Everywhere, Initiate At SellAugust 18 at 7:10 PM | seekingalpha.comTimelo Investment Management Inc. Raises Stock Position in Profound Medical (NASDAQ:PROF)August 18 at 6:55 AM | marketbeat.comProfound Medical Second Quarter 2025 Earnings: Misses ExpectationsAugust 16, 2025 | finance.yahoo.comProfound Medical Corp. (NASDAQ:PROF) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comProfound Medical Corp (PROF) Q2 2025 Earnings Call Highlights: Navigating Challenges with ...August 15, 2025 | gurufocus.comProfound Medical targets 70–75% revenue growth in 2025 as TULSA-AI and CAPTAIN trial progress fuel confidenceAugust 15, 2025 | msn.comQ2 2025 Profound Medical Corp Earnings Call TranscriptAugust 14, 2025 | gurufocus.comProfound Medical (PROF) Aims for 75% Revenue Growth Despite Q2 LossAugust 14, 2025 | gurufocus.comProfound Medical Corp. (PROF) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comProfound Medical (PROF) Reports Q2 Loss, Misses Revenue EstimatesAugust 14, 2025 | zacks.comProfound Medical Reports Q2 2025 Growth and New Innovations in Prostate TreatmentAugust 14, 2025 | tipranks.comProfound Medical Announces Second Quarter 2025 Financial ResultsAugust 14, 2025 | financialpost.comFProfound Medical Announces Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.comAltium Capital Management LLC Sells 124,411 Shares of Profound Medical (NASDAQ:PROF)August 14, 2025 | marketbeat.comProfound Medical (PROF) Projected to Post Earnings on ThursdayAugust 7, 2025 | marketbeat.comProfound Medical to Announce Q2 2025 Financial ResultsJuly 24, 2025 | tipranks.comProfound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to FollowJuly 24, 2025 | financialpost.comFProfound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to FollowJuly 24, 2025 | globenewswire.com'Profound Sadness': Colleagues, Friends Mourn Beloved East End Doctor Who Died During TriathlonJuly 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025AMD’s Results Sparked a Sell-Off—But That’s Your Buy SignalBy Thomas Hughes | August 6, 2025These 3 Stocks Could Help You Compound Wealth for Years to ComeBy Gabriel Osorio-Mazilli | July 28, 2025Zebra Technologies: Riding the Automation Wave to ProfitsBy Thomas Hughes | August 5, 2025The 4 Dividend Stocks Smart Money Is Grabbing Right NowBy Thomas Hughes | July 24, 2025NEPH, INFU, PROF, and ELMD Company DescriptionsElectromed NYSE:ELMD$19.02 -0.59 (-3.01%) Closing price 04:00 PM EasternExtended Trading$19.04 +0.02 (+0.08%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.InfuSystem NYSE:INFU$9.61 +0.01 (+0.10%) Closing price 04:00 PM EasternExtended Trading$9.62 +0.01 (+0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Nephros NASDAQ:NEPH$4.02 -0.06 (-1.47%) Closing price 04:00 PM EasternExtended Trading$4.03 +0.01 (+0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Profound Medical NASDAQ:PROF$4.60 -0.04 (-0.86%) Closing price 04:00 PM EasternExtended Trading$4.64 +0.04 (+0.87%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Rocket Lab Stock: Breakout Brewing or Time for Patience? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access